^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Talzenna (talazoparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Excerpt:
PARP inhibitor monotherapy (olaparib or talazoparib) should be considered for patients with germline pathogenic BRCA1/2 mutations...as an option for those with somatic pathogenic or likely pathogenic BRCA1/2 or germline PALB2 mutations.
DOI:
https://doi.org/10.1016/j.annonc.2021.09.019.
Source:
Title:
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Excerpt:
...Deleterious or suspected deleterious mutation in PALB2 assessed by Clinical Laboratory Improvement Amendments (CLIA) approved tumor next generation sequencing (NGS) or germline assay....
Trial ID:
Source:
Title:
Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes.
Excerpt:
Of 12 response evaluable pts with breast cancer, 3 had a RECIST response (ORR = 25%, 2 gPALB2, 1 gCHEK2/gFANCA/sPTEN) and 3 additional pts (gPALB2, sATR, sPTEN) had SD ≥ 6 months (CBR = 50%).
DOI:
10.1200/JCO.2019.37.15_suppl.3006
Trial ID:
